Severe haemophilia A with haemarthrosis improved on emicizumab: A case report
Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes i...
Saved in:
Main Authors: | Wasifuddin Mustafa, Al-Gaithi Ibrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2025-03-01
|
Series: | The Journal of Haemophilia Practice |
Subjects: | |
Online Access: | https://doi.org/10.2478/jhp-2025-0004 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience
by: Mwakichako Rebbecca Wughanga, et al.
Published: (2025-03-01) -
Clinical profile and outcome of children with haemophilia A: The Royal Hospital, Oman’s experience
by: AlRawahi Anood, et al.
Published: (2025-03-01) -
Lessons from a qualitative study of treatment experiences and perceptions in people with haemophilia in France
by: Castet Sabine-Marie, et al.
Published: (2025-04-01) -
Incidence and prevention of post-immunisation bleeding complications in people with haemophilia at a treatment centre in India
by: Zompa Tenzin, et al.
Published: (2025-06-01) -
Safety of Biological Medicinal Products for Hereditary Coagulopathies: An Analysis of the Russian Pharmacovigilance Database
by: D. S. Fokina, et al.
Published: (2025-06-01)